- Meeting abstract
- Open Access
Zinc as diagnostic marker of cancers
- Katarzyna Kaczmarek1Email author,
- Magdalena Muszyńska2,
- Katarzyna Jaworska-Bieniek1,
- Wojciech Marciniak2,
- Grzegorz Sukiennicki1,
- Marcin Lener1,
- Katarzyna Durda1,
- Tomasz Gromowski1,
- Tomasz Huzarski1,
- Tomasz Byrski1,
- Jacek Gronwald1,
- Oleg Oszurek1,
- Cezary Cybulski1,
- Tadeusz Dębniak1,
- Antoni Morawski2,
- Anna Jakubowska1 and
- Jan Lubiński1, 2
© Kaczmarek et al. 2015
- Published: 26 November 2015
- Prostate Cancer
- Colorectal Cancer
- Inductively Couple Plasma Mass Spectrometry
- Laryngeal Cancer
- Zinc Level
Zinc is a micronutrient which is essential for human health, playing a role as a cofactor of enzymes such as dehydrogenases, peptidases and component of zinc finger domains. In organism zinc is involved in metabolic pathways, immune processes, maintaining ion balance between other elements. Recently, it has been reported that zinc may play role in chemoprevention, and its level may be associated with occurrence of cancers.
The aim of the study was to evaluate a possible correlation between serum Zn level and occurrence of prostate, colorectal and laryngeal cancers. This will allow to determine whether serum Zn level may be used as an indicator which patients should be subjected for further cancer diagnostics.
The study has been conducted in 3 groups: 197 prostate cancer cases and 197 controls, 101 colorectal cancer cases and 101 controls, 109 laryngeal cancer cases and 109 controls.
Zinc level in serum was measured in all individuals by inductively coupled plasma mass spectrometry (ICP-MS) using Elan DRC-e ICP-Mass Spectrometer, Perkin Elmer.
After obtaining results from mass spectrometry, individuals in each group were divided into 4 quartiles. Comparison of number of cases and controls was performed in each quartile. Risk of cancer occurrence was evaluated with regards to the reference category - the lowest zinc level.
We have observed that high serum Zn level (>991 µg/l) was associated with higher incidence of prostate cancers (OR = 2.43; p < 0.003; CI 1.370 - 4.309). In contrast, high level of Zn (>959 µg/l) was associated with decreased incidence of laryngeal cancers (OR = 0.08; p < 0.0001; CI 0.03122 - 0.1918). In group of colorectal cancers we have not found any correlation between Zn level and cancer occurrence.
Results of our study suggest that high level of Zn may be an indicator for prostate examination (ex. PSA, biopsy) and low level of Zn may be an indicator for laryngeal examination. Serum Zn level assessment may improve cancer screening by suggesting which patients should be subjected for further testing. Such procedure may increase early detection of cancer. Our results seem to be promising and the study will be also conducted in groups of breast and lung cancers.
This work was financially supported by National Science Centre grant no. 2012/07/N/NZ4/02433.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.